REG - Synairgen plc - Grant of Options
06/07/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220706:nRSF4361Ra&default-theme=true
RNS Number : 4361R Synairgen plc 06 July 2022
Synairgen plc
('Synairgen' or the 'Company')
Grant of Options
Southampton, UK - 6 July 2022: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001, an investigational formulation for inhalation
containing the broad-spectrum antiviral protein interferon beta, announces
that on 5 July 2022 the Board of Synairgen granted options ('Options') over
6,407,130 ordinary shares of one pence each in the capital of the Company
('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The
Options represent in aggregate 3.18 per cent. of the Company's issued share
capital.
Following this grant, Synairgen has 14,891,262 options in issue, representing
7.39 per cent. of the Company's issued share capital.
Certain Options were issued to Directors of the Company and Persons
Discharging Managerial Responsibilities ('PDMR'):
Options issued 5 July 2022 Total options Ordinary shares Total interest Percentage holding of fully diluted share capital
Directors
Richard Marsden(1) 534,482 2,813,995 995,771 3,809,766 1.76%
Dr. Phillip Monk 387,931 2,034,254 423,934 2,458,188 1.14%
John Ward 387,931 2,160,889 734,092 2,894,981 1.34%
PDMRs
Jody Brookes 515,000 979,166 - 979,166 0.45%
Brooke Clarke(2) 515,000 628,636 8,520 637,156 0.29%
Richard Francis 515,000 628,636 - 628,636 0.29%
Richard Hennings 515,000 757,568 - 757,568 0.35%
Gareth Walters 515,000 635,779 - 635,779 0.29%
1. Richard Marsden's shareholding includes 184,821 shares held in his
pension plan.
2. Brooke Clarke's shareholding is held by her spouse.
The Options are issued under the Company's Long Term Incentive Plan and are
exercisable up to 4 July 2032, subject to the achievement of appropriate
performance criteria which match the criteria for the 2021 award as set out on
page 24 of the 2021 annual report.
This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No. 596/2014 ('MAR')
For further enquiries, please contact:
Synairgen plc
Brooke Clarke, Head of Communications
Media@synairgen.com (mailto:Media@synairgen.com)
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott, Namrata Taak, Lucy Featherstone
cscsynairgen@consilium-comms.com (mailto:cscsynairgen@consilium-comms.com)
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com (mailto:MConway@MKCStrategies.com)
Tel: +1 516-606-6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug discovery,
development and commercialisation. The Company's primary focus is developing
SNG001 (inhaled interferon beta) for the treatment of severe viral lung
infections, including COVID-19, as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the lungs. SNG001
has been granted Fast Track status from the US Food and Drug Administration
(FDA). Founded by University of Southampton Professors Sir Stephen Holgate,
Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE:
SNG). For more information about Synairgen, please see www.synairgen.com
(http://www.synairgen.com) .
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person
closely associated with them ('PCA')
a) Name Richard Marsden
2. Reason for notification
a) Position / status Chief Executive Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 534,482 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 5 July 2022
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person
closely associated with them ('PCA')
a) Name Dr Phillip Monk
2. Reason for notification
a) Position / status Chief Scientific Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 387,931 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 5 July 2022
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person
closely associated with them ('PCA')
a) Name John Ward
2. Reason for notification
a) Position / status Chief Financial Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 387,931 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 5 July 2022
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person
closely associated with them ('PCA')
a) Name Jody Brookes
2. Reason for notification
a) Position / status Head of Clinical Operations
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 515,000 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 5 July 2022
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person
closely associated with them ('PCA')
a) Name Brooke Clarke
2. Reason for notification
a) Position / status Head of Communications
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 515,000 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 5 July 2022
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person
closely associated with them ('PCA')
a) Name Richard Francis
2. Reason for notification
a) Position / status Head of CMC
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 515,000 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 5 July 2022
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person
closely associated with them ('PCA')
a) Name Richard Hennings
2. Reason for notification
a) Position / status Chief Commercial Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 515,000 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 5 July 2022
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person
closely associated with them ('PCA')
a) Name Gareth Walters
2. Reason for notification
a) Position / status Chief Regulatory Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 515,000 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 5 July 2022
f) Place of the transaction Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHEAEXSEAPAEAARecent news on Synairgen
See all newsRCS - Synairgen PLC - Board and Executive Leadership Changes
AnnouncementRCS - Synairgen PLC - Shares Admitted to Trading on Asset Match
AnnouncementREG - AIM Synairgen plc - Cancellation - Synairgen plc
AnnouncementREG - Synairgen plc - Update on trading post cancellation
AnnouncementREG - Synairgen plc - Result of General Meeting
Announcement